Search

Your search keyword '"Mercedes Sánchez Mateos"' showing total 4 results
Start Over Author "Mercedes Sánchez Mateos"
4 results on '"Mercedes Sánchez Mateos"'

1. <scp>Cost‐effectiveness</scp> of omalizumab for the treatment of severe pediatric allergic asthma—Results of a <scp>real‐life</scp> study in Spain

Author

María Nieto‐Cid, Teresa Garriga‐Baraut, Ana Mª. Plaza‐Martín, Miguel Tortajada‐Girbés, Javier Torres‐Borrego, Jaime Lozano‐Blasco, Laura Moreno‐Galarraga, Mª. del Mar Folqué‐Giménez, Montse Bosque‐García, Mirella Gaboli, Alejandro López‐Neyra, Cristina Rivas‐Juesas, Mª. Araceli Caballero‐Rabasco, Andrea Freixa‐Benavente, Laura Valdesoiro‐Navarrete, Inés de Mir‐Messa, Esther Ballester‐Asensio, María Penín‐Antón, Raquel Romero‐García, Juan Navarro‐Morón, Alfredo Valenzuela‐Soria, Mercedes Sánchez‐Mateos, José Batlles‐Garrido, Verónica Sanz‐Santiago, Álvaro Gimeno‐Díaz de Atauri, Anselmo Andrés‐Martín, Elena Campos‐Alonso, David Gómez‐Pastrana, Elena Vázquez‐Rodríguez, Luz Martínez‐Pardo, Genoveva del Río‐Camacho, Ángel Mazón‐Ramos, and Antonio Nieto‐García

Subjects
Immunology, Pediatrics, Perinatology and Child Health, Immunology and Allergy
Published
2023

2. COST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF SEVERE PEDIATRIC ALLERGIC ASTHMA- RESULTS OF A REAL-LIFE STUDY IN SPAIN

Author

Antonio Nieto, María Nieto-Cid, Teresa Garriga-Baraut, Ana Plaza, Miguel Tortajada, Javier Torres-Borrego, Lozano Jaime, Laura Moreno-Galarraga, Mar Folque, Montserrat Bosque, Mirella Gaboli, Alejandro López Neyra, Cristina Rivas-Juesas, María Araceli Caballero-Rabasco, Andrea Freixa, Laura Valdesoiro Navarrete, Esther Ballester Asensio, María Penín Antón, Raquel Romero, Juan Navarro Morón, Alfredo Valenzuela-Soria, Mercedes Sánchez Mateos, José Batlles Garrido, Verónica Sanz Santiago, Álvaro Gimeno Díaz de Atauri, Anselmo Andrés Martín, Elena Campos Alonso, David Gómez-Pastrana, Elena Vázquez Rodríguez, Luz Martínez-Pardo, Genoveva del Río Camacho, and Angel Mazón Ramos

Abstract

BACKGROUND Severe Pediatric Allergic Asthma (SPAA) induces a huge economic burden in terms of direct, indirect and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective. METHODS A sample of 426 children with SPAA from the ANCHORS study was used to calculate the Incremental Cost Effectiveness Ratio (ICER) for the avoidance of Moderate to Severe Exacerbations (MSE), and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data of health encounters and drug consumption before and up to six years after the beginning of the treatment with omalizumab. RESULTS The ICER per avoided MSE was \euro2,107 after one year, and it consistently decreased to \euro656 in those followed up to six years. Similarly, the ICER for the Minimally Important Difference in control tests showed a decrease from \euro2,059 to \euro380 per each 0.5 points of improvement in ACQ5, and from \euro3,141 to \euro2,322 per each 3 points improvement in c-ACT, at years 1 and 6 respectively. CONCLUSION The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, mainly those who have frequent exacerbations, showing progressively reduced costs in successive years of treatment.

Published
2023

3. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

Author

Cristina Rivas Juesas, Montserrat Bosque, Luz Martínez Pardo, Mercedes Sánchez Mateos, Alfredo Valenzuela Soria, Miguel Tortajada, Ángel Mazón Ramos, A.M. Plaza, María Nieto Cid, Genoveva del Río Camacho, José Batlles Garrido, Esther Ballester Asensio, Antonio Nieto Garcia, Raquel Romero, Teresa Garriga-Baraut, Elena Vázquez Rodríguez, María Penín Antón, Laura Valdesoiro Navarrete, María Araceli Caballero-Rabasco, Jaime Lozano, Verónica Sanz Santiago, E. Alonso, Alejandro López Neyra, Carmen Aragón Fernández, M M Folque, Juan Navarro Morón, A. Andrés Martín, Álvaro Gimeno Díaz de Atauri, Javier Torres-Borrego, Laura Moreno-Galarraga, Andrea Freixa, and Mirella Gaboli

Subjects
severe asthma, medicine.medical_specialty, Pediatrics, Immunology, real life, Omalizumab, humanized monoclonal antibodies, adolescents, Antibodies, Monoclonal, Humanized, Anti-asthmatic Agent, 03 medical and health sciences, 0302 clinical medicine, children, Internal medicine, medicine, anti-asthmatic agents, Humans, Immunology and Allergy, Children, adolescents, anti-asthmatic agents, humanized monoclonal antibodies, observational study, omalizumab, real-life, severe asthma, Anti-Asthmatic Agents, 030212 general & internal medicine, Child, Adverse effect, Retrospective Studies, business.industry, asthmatic agents, observational study, anti&#8208, Retrospective cohort study, Asthma, Discontinuation, omalizumab, Treatment Outcome, Pulmonology, 030228 respiratory system, Severe persistent allergic asthma, Pediatrics, Perinatology and Child Health, Cohort, Observational study, business, medicine.drug
Abstract

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients

Published
2021

4. Author response for 'Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma'

Author

Javier Torres Borrego, Antonio Nieto Garcia, Álvaro Gimeno Díaz de Atauri, Ana Mª Plaza Martín, María del Mar Folqué Giménez, A. Andrés Martín, Genoveva del Río Camacho, Luz Martínez Pardo, Montse Bosque García, Miguel Tortajada-Girbés, Alejandro López Neyra, Mercedes Sánchez Mateos, Jaime Lozano Blasco, Andrea Freixa, E. Alonso, Esther Ballester Asensio, Laura Moreno-Galarraga, Juan Navarro Morón, Mirella Gaboli, Carmen Aragón Fernández, Ángel Mazón Ramos, Alfredo Valenzuela Soria, Raquel García, Cristina Rivas Juesas, María Nieto Cid, Laura Valdesoiro Navarrete, Verónica Sanz Santiago, Teresa Garriga-Baraut, María Araceli Caballero-Rabasco, Elena Vázquez Rodríguez, José Batlles Garrido, and María Penín Antón

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Severe persistent allergic asthma, Medicine, Omalizumab, business, medicine.drug
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results